Clinical Trial

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration of venetoclax plus acalabrutinib (AV) in participants with previously untreated chronic lymphocytic leukemia (CLL).
Protocol Amendment History 9 changes
notable Trial sites expanded: 91 -> 96 locations 2026-08-07
notable Trial sites expanded: 88 -> 91 locations 2026-07-24
notable Trial sites expanded: 77 -> 88 locations 2026-07-11
notable Trial sites expanded: 66 -> 77 locations 2026-06-19
notable Trial sites expanded: 46 -> 66 locations 2026-06-04
notable Trial sites expanded: 29 -> 46 locations 2026-05-28
notable Trial sites expanded: 24 -> 29 locations 2026-05-12
notable Trial sites expanded: 20 -> 24 locations 2026-04-23
notable Trial sites expanded: 14 -> 20 locations 2026-04-16
Trial Details
NCT Number NCT07277231
Lead Sponsor BeOne Medicines
Conditions Chronic Lymphocytic Leukemia
Enrollment 500 participants
Start Date 2026-01-22
Primary Completion 2031-02 (estimated)
Study Completion 2031-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-06